文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

玻璃体腔注射雷珠单抗初始治疗1型早产儿视网膜病变后周边视网膜血管的荧光素血管造影评估

FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY.
PubMed 文献 · Retina · 2019-01-01

本研究回顾性评估了16例(30眼)因1型早产儿视网膜病变接受玻璃体腔注射雷珠单抗初始治疗的新生儿,在矫正胎龄44至150周行荧光素血管造影。结果显示仅50%患眼血管化达III区,40%存在持续性血管渗漏,≥90%有血管变钝、扩张和/或毛细血管无灌注。

要点

  • 接受雷珠单抗初始治疗的1型早产儿视网膜病变患眼中,仅50%血管化达III区。
  • 40%患眼在矫正胎龄44至150周时仍存在持续性血管渗漏。
  • ≥90%患眼荧光素血管造影显示血管变钝、血管扩张和/或毛细血管无灌注。

核心结论

  • 尽管玻璃体腔注射雷珠单抗能有效初始控制1型早产儿视网膜病变,但本系列中仅50%患眼血管化达III区,且多数患眼荧光素血管造影显示血管异常。
  • 作者认为,若未来开展比较激光光凝与抗血管内皮生长因子治疗的研究,应考虑行荧光素血管造影评估周边视网膜血管状态以判断治疗效果。

研究设计与样本

  • 回顾性评估2013年4月至2015年1月间因1型早产儿视网膜病变接受玻璃体腔注射雷珠单抗初始治疗的16例新生儿共30眼的荧光素血管造影结果。
  • 结局指标包括血管化达III区、血管变钝、血管环、血管扩张、毛细血管无灌注和血管荧光素渗漏。

主要发现

  • 平均胎龄24周,玻璃体腔注射雷珠单抗治疗时平均矫正胎龄35周。
  • 矫正胎龄44至150周行荧光素血管造影显示,仅50%患眼血管化达III区。
  • 40%患眼存在持续性血管渗漏。
  • ≥90%患眼显示血管变钝、血管扩张和/或毛细血管无灌注。

临床怎么用

  • 原文结论未据此给出具体临床推荐,仅建议未来比较激光光凝与抗血管内皮生长因子的研究可考虑行荧光素血管造影评估周边视网膜血管状态。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate angiographic findings in neonates up to 150 weeks postmenstrual age who received intravitreal ranibizumab for primary treatment of Type 1 retinopathy of prematurity. METHODS: Retrospective evaluation of fluorescein angiogram findings was completed for 30 eyes of 16 neonates who received intravitreal ranibizumab as primary treatment for Type 1 retinopathy of prematurity between April 2013 and January 2015. Outcome measures included maturity to Zone III, vascular blunting, vascular loops, vascular dilatation, capillary dropout, and vascular fluorescein leakage. RESULTS: Mean gestational age was 24 weeks and mean postmenstrual age at time of intravitreal ranibizumab treatment was 35 weeks. Fluorescein angiograms performed at 44 weeks to 150 weeks postmenstrual age showed only 50% of eyes reached vascularization to Zone III; 40% had persistent vascular leakage; and ≥90% exhibited vascular blunting, vascular dilatation, and/or capillary dropout. CONCLUSION: Although intravitreal ranibizumab is effective in initial cessation of Type 1 retinopathy of prematurity, vascularization to Zone III was only achieved in 50% of eyes in our series and most eyes had fluorescein angiography evidence of vascular anomalies. If future studies are performed comparing treatment with laser photocoagulation to anti-vascular endothelial growth factor, fluorescein angiographic studies should be considered to assess the status of the peripheral retinal vasculature to determine treatment effect.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Harper CA, Wright LM, Young RC, et al. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY. Retina. 2019. PMID: 29300248. doi:10.1097/IAE.0000000000001996

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。